These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 30703143

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.
    Xiong XF, Zhu M, Wu HX, Fan LL, Cheng DY.
    Respir Res; 2019 May 31; 20(1):108. PubMed ID: 31151443
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.
    N Engl J Med; 2018 Jun 28; 378(26):2486-2496. PubMed ID: 29782217
    [Abstract] [Full Text] [Related]

  • 25. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
    Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.
    Clin Exp Allergy; 2014 Jan 28; 44(1):38-46. PubMed ID: 24131304
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Monoclonal antibodies in severe asthma: is it worth it?
    Calzetta L, Matera MG, Rogliani P.
    Expert Opin Drug Metab Toxicol; 2019 Jun 28; 15(6):517-520. PubMed ID: 31104515
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, Serone AP, Wright TJ, Jenkins MM, Panesar IS, Thiagarajah SS, Wenzel SE.
    J Allergy Clin Immunol; 2014 Apr 28; 133(4):989-96. PubMed ID: 24582316
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis.
    Wang FP, Liu T, Lan Z, Li SY, Mao H.
    PLoS One; 2016 Apr 28; 11(11):e0166833. PubMed ID: 27875559
    [Abstract] [Full Text] [Related]

  • 31. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N, Nair P.
    Curr Opin Pulm Med; 2014 Jan 28; 20(1):87-94. PubMed ID: 24275927
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
    Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.
    Respir Med; 2018 Jan 28; 134():143-149. PubMed ID: 29413502
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP, Zhang GS, Lou J, Zhou HB, Cui W.
    J Asthma; 2018 Sep 28; 55(9):956-965. PubMed ID: 29211545
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct 28; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 35. The tralokinumab story: Nothing is ever simple.
    Apter AJ.
    J Allergy Clin Immunol; 2019 Apr 28; 143(4):1336-1338. PubMed ID: 30659852
    [No Abstract] [Full Text] [Related]

  • 36. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.
    Tripp CS, Cuff C, Campbell AL, Hendrickson BA, Voss J, Melim T, Wu C, Cherniack AD, Kim K.
    Adv Ther; 2017 Jun 28; 34(6):1364-1381. PubMed ID: 28455782
    [Abstract] [Full Text] [Related]

  • 37. Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma.
    Agrawal S, Townley RG.
    Expert Opin Biol Ther; 2014 Feb 28; 14(2):165-81. PubMed ID: 24283478
    [Abstract] [Full Text] [Related]

  • 38. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators.
    Lancet; 2016 Oct 29; 388(10056):2128-2141. PubMed ID: 27609406
    [Abstract] [Full Text] [Related]

  • 39. Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma.
    N Bauer R, Yang X, L Staton T, Olsson J, Holweg CTJ, R Arron J, Matthews JG, Choy DF.
    BMJ Open Respir Res; 2019 Oct 29; 6(1):e000406. PubMed ID: 31803473
    [Abstract] [Full Text] [Related]

  • 40. Monoclonal Antibodies for the Management of Severe Asthma.
    Rubinsztajn R, Chazan R.
    Adv Exp Med Biol; 2016 Oct 29; 935():35-42. PubMed ID: 27334730
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.